Lenvatinib continuation versus regorafenib in treating hepatocellular carcinoma after lenvatinib failure
Continuing lenvatinib as second-line therapy after failure may offer sustained survival benefits and demonstrate favorable efficacy and safety in real-world clinical practice.
Authors
- Chenghao Zhao (ORCID: https://orcid.org/0009-0002-8794-1163)
- Mo Huang (ORCID: https://orcid.org/0000-0003-0497-194X)
- Tao Pan
- Huan Liu
- Luwen Mu
- Yangchao Tong
- Mingming Liu
- Huzheng Yan
- Zhanwang Xiang
Institutions
- Sun Yat-sen University (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Quantitative Imaging in Medicine and Surgery
- Published
- 2025-12-31
- DOI
- https://doi.org/10.21037/qims-2025-615
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00